ÂÜÀòÂÒÂ×

Jennifer has more than 25 years of Quality and CMC experience for CAR-T cell therapy, Antibody therapeutics, and Antibody Drug Conjugates. Jennifer is now the VP of Quality at Acepodia Biotech, Inc., an allogeneic cell therapy company specialized in a patented Antibody Cell Conjugates platform, based in the San Francisco Bay Area and with Operations in Taiwan.

Before joining Acepodia, Jennifer was the Head of Quality at JW Therapeutics in China, working on the development of an autologous CAR-T cell therapy product RelmaCel, which was approved and launched in Sept 2021. Prior to joining JW in 2018, Jennifer worked at Abbvie for 2 years, Genentech for 10 years, and Tanox for 10 years in the US, led a team of scientists/Quality specialists responsible for various CMC and Quality aspects in developing multiple Antibody based therapeutics.

Jennifer earned her B.S. in Chemistry, and M.S. in Chemical Engineering from Tsinghua University in China, and Ph.D. in Chemical Engineering from Texas A&M University in the US.